The DOI matches its Crossref record.
A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses.
Abstract
In vitro, IL-10 inhibits T cell proliferation and LPS-induced monocyte production of IL-1, TNF-alpha, IL-6, and IL-8. We studied the safety and immunomodulatory effects of IL-10 administration in humans. Seventeen healthy volunteers received a single i.v. bolus injection of either human IL-10 (1, 10, or 25 micrograms/kg) or placebo. Routine safety parameters, lymphocyte phenotypes, T cell proliferative responses, and stimulus-induced cytokine production were assessed before and 3, 6, 24, and 48 h after injection. There were no adverse symptoms or signs after IL-10 administration. A transient neutrophilia and monocytosis that peaked at 6 h (45-160% above base line) was observed. However, lymphocyte counts fell by 25% 3 and 6 h after the injection (p < 0.01). In particular, lymphocytes expressing the T cell surface markers CD2, CD3, CD4, CD7, and CD8 were significantly decreased. Mitogen-induced T cell proliferation was suppressed by up to 50% (p < 0.01) in the two higher dose groups. Significant dose-dependent inhibition (65-95%) of TNF-alpha and IL-1 beta production from whole blood stimulated ex vivo with endotoxin occurred after each dose of IL-10. In contrast, there was no reduction in the production of their respective antagonists, TNF soluble receptor p55 or IL-1 receptor antagonist. We conclude that a single intravenous injection of IL-10 is safe in humans, has inhibitory effects on T cells, and suppresses production of the pro-inflammatory cytokines TNF-alpha and IL-1 beta.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Is Type II diabetes mellitus a disease of the innate immune system?
Pickup, J. C., & Crook, M. A. (1998) · Diabetologia · doi:10.1007/s001250051058 · Cited by 1,041
Pro‐ and anti‐inflammatory cytokine balance in strenuous exercise in humans
Ostrowski, K., Rohde, T., Asp, S., Schjerling, P., & Pedersen, B. K. (1999) · The Journal of Physiology · doi:10.1111/j.1469-7793.1999.287ad.x · Cited by 1,014
Treating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
Interleukin-10 Therapy—Review of a New Approach
Asadullah, K., Sterry, W., & Volk, H. D. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.4 · Cited by 946
Metadata
- Authors
- Chernoff, A. E., Granowitz, E. V., Shapiro, L., Vannier, E., Lonnemann, G., Angel, J. B., Kennedy, J. S., Rabson, A. R., Wolff, S. M., & Dinarello, C. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-05
- Volume
- 154
- Issue
- 10
- Pages
- 5492-5499
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1560264230
- Cited by
- 418
- References
- 0
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. https://app.cochat.ai/papers/10.4049/jimmunol.154.10.5492
- The paper
- Chernoff, A. E., Granowitz, E. V., Shapiro, L., Vannier, E., Lonnemann, G., Angel, J. B., Kennedy, J. S., Rabson, A. R., Wolff, S. M., & Dinarello, C. A. (1995). A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. The Journal of Immunology. https://doi.org/10.4049/jimmunol.154.10.5492
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.